We're proud to share insights from the recent China-Vietnam Hospital Forum Day: Clinical and Management Symposium (July 29-30), where Vietnamese medical leaders Dr. NGUYỄN THỊ THU, Dr. LÊ PHÚ TÀI, Dr. LÊ SỸ HÙNG, Dr. VÕ DUY THÔNG, Dr. VŨ HUY VĂN and Dr. ĐẶNG ĐÌNH HOAN engaged in transformative exchanges at Beijing Luhe Hospital, Capital Medical University and Hebei Medical University Third Hospital.
At Beijing Luhe Hospital, led by Dr. Nannan Wu (Vice Director of Endocrinology Center), experts from University Medical Center Ho Chi Minh City, Bach Mai Hospital and Gia An 115 Hospital conducted in-depth observations of the Metabolic Management Center (MMC), where they analyzed on-site inspections of outpatient and inpatient procedures, as well as real-time implementation of iLivTouch within endocrinology workflows. Afterwards, experts from the two countries exchanged views on department construction and development, including collaboration between departments for liver disease patient management.
Following their arrival at Hebei Medical University Third Hospital, Vietnamese delegates commenced their visit with an immersive tour of the institution's History Museum, gaining profound insights into its medical legacy. Dr. Na Fu (Deputy Director of Hepatology) presented the department's pioneering care framework - detailing standardized disease diagnosis pathways, patient management protocols. Dr. Võ Duy Thông then shared the specialty development model of University Medical Center Ho Chi Minh City (UMC) and Vietnam's liver disease prevention landscape.
During the subsequent exchange session, Dr. Yuemin Nan (Director of Hepatology) shared the department’s experience in managing liver disease patients and the application of traditional Chinese medicine/Chinese patent medicine, and how iLivTouch has replaced FIB-4 as the primary screening tool across outpatient services, significantly enhancing operational efficiency. Vietnamese experts also learned from Dr. Jian Dou (Former Vice President) about liver transplantation procedures and artificial liver support systems, where Dr. Dou shared the hospital's surgical practices, patient management approaches, and clinical applications of artificial liver technology.
Hisky Medical will drive global collaborations to bridge China's innovative technologies with international clinical needs. We commit to accelerating the worldwide deployment of early liver disease screening and intervention programs. In partnership with global experts, we will catalyze transformative advancements in patient care standards.